AstraZeneca said the U.S. Food and Drug Administration (FDA) accepted its application for sonesitatug vedotin, known as Sone-Ve, and granted it priority review on Nov. 19.
The application covers certain patients with advanced gastric and related cancers, according to AstraZeneca.



